HPGDS and breast cancer: Investigated the usefulness of the nuclear matrix protein (NMP22) as a diagnostic marker in BC in terms of genetic susceptibility (slow acetylator N-acetyltransferase 2, NAT2) combined with detoxification abilities (Glutathione S-transferases, GST and the GST isoenzyme—π) [44].